CorePlus Servicios Clínicos y Patológicos, a provider in AI-based solutions for cancer detection in pathology, is scaling their expertise in 3D digital pathology with Alpenglow Biosciences’ full 3D spatial biology offering.

CorePlus was also an early adopter of AI-based tools for prostate cancer detection to support pathologists in providing accurate diagnoses.

A recent study in Cancer Research compared 2D-based AI-algorithms head-to-head with 3D AI-algorithms using Alpenglow’s open top lightsheet imager to stratify patients based on prostate cancer risk. The study found a significant improvement using computational 3D pathology techniques based on hazard ratio separation in Kaplan Meier survival curves. The results of the study suggest the use of computational 3D pathology could help guide clinical management of prostate cancer in the future following necessary regulatory clearances.

“We are excited to be making this transformational leap forward in pathology,” says Mariano de Socarraz, founder and CEO at CorePlus. “From traditional microscopy-based pathology to whole slide imaging primary diagnosis with AI and now to AI-powered 3D digital pathology, we are proud to be the first pathology laboratory in the Americas to adopt this breakthrough technology from Puerto Rico to the world.”

Alpenglow Biosciences’ 3D spatial Biology Offering

Alpenglow’s 3D offering includes an end-to-end platform solution for enabling whole-tissue digital imaging and analysis. Starting with the 3Deep Imager (3Di), Alpenglow rapidly digitizes entire blocks of tissue without ever cutting a single slide, preserving the tissue for other correlative downstream assays.

Data is managed with Alpenglow’s 3Dm cloud-based data management system to reduce the infrastructure requirements needed to handle the large 3D datasets. Finally, Alpenglow’s 3Deep Analysis (3Da) suite, powered by the latest AI and machine learning algorithms, interprets the data and provides insights only found by looking in 3D.

“We are thrilled to be bringing 3D spatial biology to CorePlus and help usher in the transformation of pathology from 2D and slide-based to 3D and digital,” says Nicholas Reder, MD, MPH, and CEO at Alpenglow. “Our 3D imaging, data management, and analysis platform combined with CorePlus’ deep expertise in AI-powered pathology make them the perfect partner to launch our product in the Americas.”

Featured image: Alpenglow Biosciences and CorePlus staff stand in front of the 3Deep Imager, an imaging platform capable of bringing AI-enabled 3D imaging to pathology. Photo: Alpenglow Biosciences